The Socioeconomic Impact of Multiple Sclerosis in France: Results from the PETALS Study

Overview

Journal Mult Scler J Exp Transl Clin

Date 2022 Apr 28

PMID 35479962

Authors

A Bouleau

C Dulong

C A Schwerer

R Delgrange

K Bouaou

T Brochu

S Zinai

K Svecova

M J Sa

A Petropoulos

S Aly

P Labauge

Affiliations

Soon will be listed here.

Abstract

Background: Multiple sclerosis (MS) places a considerable financial burden on the society. However, data quantifying the contemporary cost burden in France are lacking.

Objective: This cost-of-illness study aimed to estimate the direct and indirect costs associated with MS in France.

Methods: Between October 2020-November 2020, 208 French adults with a confirmed diagnosis of MS were recruited via MSCopilot (a new MS self-assessment digital solution) and several MS patient networks. Indirect costs were estimated using a combination of top-down and bottom-up approaches. Direct costs were retrieved from Assurance Maladie (i.e. national system of health insurance) publications. Out-of-pocket expenses (OOPEs) incurred by MS patients were also reported. All costs were expressed in €2020. Data from the survey were extrapolated to the overall French MS population.

Results: MS exerted an annual cost burden of €2.7 billion on the French society (indirect costs: €1.3 billion; direct costs: €1.4 billion). Mean annual costs were €27,164.7 per-patient, with indirect and direct costs accounting for 48.1% and 51.9% of the total annual costs, respectively. OOPEs contributed over €90 million to the total annual costs.

Conclusions: MS imposes a substantial cost burden on the French society, with approximately half of the total annual costs driven by indirect costs.

Citing Articles

The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event.

Zaratin P, Samadzadeh S, Seferoglu M, Ricigliano V, Silva J, Tunc A Front Neurol. 2024; 15:1407257.

PMID: 38974689 PMC: 11225898. DOI: 10.3389/fneur.2024.1407257.

References

Dobson R, Giovannoni G . Multiple sclerosis - a review. Eur J Neurol. 2018; 26(1):27-40. DOI: 10.1111/ene.13819. View

Biernacki T, Sandi D, Kincses Z, Fuvesi J, Rozsa C, Matyas K . Contributing factors to health-related quality of life in multiple sclerosis. Brain Behav. 2019; 9(12):e01466. PMC: 6908891. DOI: 10.1002/brb3.1466. View

Kobelt G, Texier-Richard B, Lindgren P . The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult Scler. 2009; 15(6):741-51. DOI: 10.1177/1352458509102771. View

Yalachkov Y, Soydas D, Bergmann J, Frisch S, Behrens M, Foerch C . Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019; 30:33-37. DOI: 10.1016/j.msard.2019.01.049. View

Ernstsson O, Gyllensten H, Alexanderson K, Tinghog P, Friberg E, Norlund A . Cost of Illness of Multiple Sclerosis - A Systematic Review. PLoS One. 2016; 11(7):e0159129. PMC: 4943600. DOI: 10.1371/journal.pone.0159129. View

Garcia-Dominguez J, Maurino J, Martinez-Gines M, Carmona O, Caminero A, Medrano N . Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health. 2019; 19(1):609. PMC: 6528334. DOI: 10.1186/s12889-019-6907-x. View

Lebrun-Frenay C, Kobelt G, Berg J, Capsa D, Gannedahl M . New insights into the burden and costs of multiple sclerosis in Europe: Results for France. Mult Scler. 2017; 23(2_suppl):65-77. DOI: 10.1177/1352458517708125. View

Karampampa K, Gustavsson A, Miltenburger C, Eckert B . Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012; 18(2 Suppl):7-15. DOI: 10.1177/1352458512441566. View

Pike J, Grosse S . Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review. Appl Health Econ Health Policy. 2018; 16(6):765-778. PMC: 6467569. DOI: 10.1007/s40258-018-0416-4. View

10.

Foulon S, Maura G, Dalichampt M, Alla F, Debouverie M, Moreau T . Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data. J Neurol. 2017; 264(6):1185-1192. PMC: 5486573. DOI: 10.1007/s00415-017-8513-0. View

11.

Chen J, Taylor B, Blizzard L, Simpson Jr S, Palmer A, van der Mei I . Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry. 2018; 89(11):1200-1207. DOI: 10.1136/jnnp-2018-318228. View

12.

Koopmanschap M, Rutten F . The consequence of production loss or increased costs of production. Med Care. 1996; 34(12 Suppl):DS59-68. View

13.

Lefeuvre D, Rudant J, Foulon S, Alla F, Weill A . Healthcare expenditure of multiple sclerosis patients in 2013: A nationwide study based on French health administrative databases. Mult Scler J Exp Transl Clin. 2017; 3(3):2055217317730421. PMC: 5600306. DOI: 10.1177/2055217317730421. View

14.

Paz-Zulueta M, Paras-Bravo P, Cantarero-Prieto D, Blazquez-Fernandez C, Oterino-Duran A . A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020; 43:102162. DOI: 10.1016/j.msard.2020.102162. View

15.

Bruno D, Marc D, Ouarda P, Dominique S, Marc S, Laurene C . Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord. 2019; 36:101396. DOI: 10.1016/j.msard.2019.101396. View

16.

Fromont A, Lehanneur M, Rollot F, Weill A, Clerc L, Bonithon Kopp C . [Cost of multiple sclerosis in France]. Rev Neurol (Paris). 2014; 170(6-7):432-9. DOI: 10.1016/j.neurol.2014.02.007. View

17.

Koopmanschap M, Rutten F . A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996; 10(5):460-6. DOI: 10.2165/00019053-199610050-00003. View

18.

Ruutiainen J, Viita A, Hahl J, Sundell J, Nissinen H . Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. J Med Econ. 2015; 19(1):21-33. DOI: 10.3111/13696998.2015.1086362. View

19.

Heinzlef O, Molinier G, van Hille B, Radoszycki L, Dourgnon P, Longin J . Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France. Pharmacoecon Open. 2020; 4(4):593-603. PMC: 7688762. DOI: 10.1007/s41669-020-00199-7. View

20.

He A, Merkel B, Brown J, Zhovits Ryerson L, Kister I, Malpas C . Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020; 19(4):307-316. DOI: 10.1016/S1474-4422(20)30067-3. View